StreetInsider.com News Articles

StoneX Reiterates Speculative Buy Rating on Humacyte (HUMA)

Fri, 16 Oct 2026 10:05:42 -0400

StoneX analyst Bruce D. Jackson reiterated a Speculative Buy rating and $1.00 price target on Humacyte (NASDAQ: HUMA).

The analyst commented, "Humacyte says the number of hospitals ordering Symvess increased to 49 at the end of 3Q, up from 34 at the end of 2Q, showing that the retooled marketing effort is beginning to work. The company hinted that new hospital ordering activity increased sequentially during the quarter but did not provide any overall utilization metrics. No change to our revenue estimates, which assumed 49 hospitals. We estimate that Humacyte will formally report 3Q results in November."

For an analyst ratings summary

H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)

Fri, 16 Oct 2026 08:12:30 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $4.00 price target on Humacyte (NASDAQ: HUMA).

The analyst commented: "On October 15, Humacyte reported that 15 additional hospitals ordered Symvess, its acellular tissue engineered vessel (ATEV) approved by the FDA for extremity vascular trauma. This represents a sequential increase of 44%, bringing the cumulative number of ordering hospitals to 49 at the end of 3Q26 (vs 34 at the end of 2Q26). We view the 15 additional ordering hospitals as a tangible indicator that management has been executing on the commercial rebuild to generate a 2H26 ramp, and that the

Humacyte reports 44% rise in Symvess hospital orders in Q3

Thu, 15 Oct 2026 08:06:35 -0400

Humacyte, Inc. (Nasdaq: HUMA) reported that the number of hospitals ordering its Symvess vascular graft increased 44% during the third quarter of 2026, rising from 34 hospitals at the end of the second quarter to 49 hospitals as of September 30, 2026, according to a company statement.

Symvess is an FDA-approved acellular tissue engineered vessel (ATEV) indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and autologous vein graft is not feasible. The FDA approved the product in December 2024.

The company said new hospital ordering activity increased

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Thu, 15 Oct 2026 08:00:00 -0400

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.

– Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

DURHAM, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today provided a commercial update highlighting increasing momentum in the launch of Symvess, its FDA-approved acellular tissue engineered vessel (ATEV) for vascular trauma. Symvess is

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Thu, 15 Oct 2026 08:00:00 -0400

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.

– Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest.

Humacyte Phase 3 trial data to be presented at ASN Kidney Week

Mon, 12 Oct 2026 08:00:28 -0400

Humacyte, Inc. (Nasdaq: HUMA) announced that interim results from its V012 Phase 3 clinical trial have been accepted for a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2026, scheduled for October 21–25 in Denver, Colorado.

The V012 trial is a randomized controlled study comparing Humacyte's acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula for hemodialysis access in female patients with end-stage kidney disease. The presentation is scheduled for October 22, 2026, at 4:40 PM MT at the Colorado Convention Center.

Prabir Roy-Chaudhury, M.D., Ph.D., of the University of North Carolina at Chapel Hill School of Medicine will

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Mon, 12 Oct 2026 08:00:00 -0400

- Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals.

– Randomized trial compares the acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula in female patients with end-stage kidney disease.

– Supplemental BLA in AV access for hemodialysis expected to be submitted to FDA this quarter.

DURHAM, N.C., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that interim results from

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Mon, 12 Oct 2026 08:00:00 -0400

- Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals.

– Randomized trial compares the acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula in female patients with end-stage kidney disease.

– Supplemental BLA in AV access for hemodialysis expected to be submitted to FDA this quarter.

Form 4 Humacyte, Inc. For: Oct 06 Filed by: COWARD D SCOTT

Wed, 07 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261007/27161282.html

Form 4 Humacyte, Inc. For: Oct 06 Filed by: Kuznik Paul Brian

Wed, 07 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261007/27161245.html

Barclays Starts Humacyte (HUMA) at Equalweight

Tue, 06 Oct 2026 16:25:48 -0400

Barclays analyst Matt Miksic initiates coverage on Humacyte (NASDAQ: HUMA) with a Equalweight rating and a price target of $0.50.

For an analyst ratings summary and ratings history on Humacyte click here. For more ratings news on Humacyte click here.

Shares of Humacyte closed at $0.50 yesterday.

Form 3 Humacyte, Inc. For: Sep 22 Filed by: Kuznik Paul Brian

Mon, 28 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27114518.html

Form 3 Humacyte, Inc. For: Sep 22 Filed by: COWARD D SCOTT

Mon, 28 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260928/27114500.html

Form 8-K Humacyte, Inc. For: Sep 22

Mon, 28 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27114467.html

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Mon, 28 Sep 2026 08:00:00 -0400

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.

“We are delighted to welcome two distinguished commercialization and life science leaders to the Humacyte Board as we continue to expand our ongoing Symvess® launch and prepare for our planned commercial launch of

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

Mon, 28 Sep 2026 08:00:00 -0400

Form 4 Humacyte, Inc. For: Sep 14 Filed by: Jones Keith Anthony

Tue, 15 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260915/27064837.html

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also be available for one-on-one meetings.

Event: H.C. Wainwright 28th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York, NY
Presentation: Wednesday, September 16, 2026 at 11:00am ET
Webcast: click here

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 08:00:00 -0400

FDA extends Symvess shelf life from 18 to 36 months

Wed, 09 Sep 2026 08:07:46 -0400

Humacyte, Inc. (NASDAQ: HUMA) announced that the U.S. Food and Drug Administration has authorized an extension of the expiration dating period for its Symvess vascular graft product from 18 months to 36 months when stored refrigerated at 2°C to 8°C.

The extension is supported by stability data showing Symvess continues to meet product quality specifications throughout the extended period under approved storage conditions. No changes to storage requirements are involved.

"Extending the shelf life to 36 months provides greater inventory flexibility while maintaining the same storage requirements and approved clinical use," said Laura Niklason, MD, PhD, Founder, President and Chief Executive Officer

FDA extends Symvess shelf life from 18 to 36 months

Wed, 09 Sep 2026 08:07:46 -0400

Form 25-NSE Humacyte, Inc. Filed by: Nasdaq Stock Market LLC

Tue, 25 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260825/26974990.html

Form 25-NSE Humacyte, Inc. Filed by: Nasdaq Stock Market LLC

Tue, 25 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260825/26974990.html

Humacyte plans supplemental BLA filing for dialysis use in Nov. 2026

Mon, 24 Aug 2026 08:03:29 -0400

Humacyte, Inc. (Nasdaq: HUMA) announced that discussions with the Food and Drug Administration confirm the company's plan to file a supplemental Biologics License Application for its acellular tissue engineered vessel (ATEV) in dialysis access in November 2026.

The filing would seek to add dialysis access as a second approved indication for the ATEV, following its December 2024 FDA approval for vascular trauma. The supplemental BLA will be supported by results from three Phase 3 studies, including the V012 trial, the V007 study, and the V006 study.

The V012 trial, conducted in female dialysis access patients, found that women who received the ATEV

Humacyte plans supplemental BLA filing for dialysis use in Nov. 2026

Mon, 24 Aug 2026 08:03:29 -0400

The V012 trial, conducted in female dialysis access patients, found that women who received the ATEV